Understanding genetic variants in lung adenocarcinoma among Mexican patients
Prevalence of Pathogenic or Likely Pathogenic Germline Variants in Cancer Predisposition Genes Among Patients With Lung Adenocarcinoma
This study is trying to find out how common certain genetic changes are in Mexican patients under fifty with lung adenocarcinoma to better understand their condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 332 (estimated) |
| Ages | 16 Years to 85 Years |
| Sex | All |
| Sponsor | Instituto Nacional de Cancerologia de Mexico Academic / other |
| Locations | 1 site (Mexico City, Mexico City) |
| Trial ID | NCT06181812 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prevalence of germline pathogenic variants in Mexican patients diagnosed with lung adenocarcinoma, particularly focusing on those under fifty years of age. It will explore the clinical-pathological characteristics associated with these variants and investigate the relationship between actionable somatic mutations and germline variants. Participants will provide a blood sample for DNA extraction and next-generation sequencing to identify genetic alterations. The study is designed to gather comprehensive data that could enhance understanding of lung adenocarcinoma genetics in this population.
Who should consider this trial
Good fit: Ideal candidates include Mexican patients aged 16 and older with histologically confirmed lung adenocarcinoma.
Not a fit: Patients without accessible blood samples or insufficient clinical information may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved genetic screening and targeted therapies for lung adenocarcinoma patients.
How similar studies have performed: Other studies have shown success in identifying genetic variants in lung cancer, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Both sexes * ≥ 16 years old, according the institutional protocols for new patients admittances. * histologically confirmed lung adenocarcinoma (LUAD) * Signed written informed consent form * A life expectancy greater than 8 weeks. * Histologically confirmed LUAD and one of the following conditions: i) LCFH, defined as having one first-degree relative (FDR) or two or more second-degree relatives with LC, irrespective of the age at diagnosis. ii) Age at diagnosis ≤50 years, or ≤60 with a pack-years index. iii) Presence of ≥1 AGAs (EGFR, ALK, ROS1, KRAS, BRAF, MET exon 14 skipping, or RET). Exclusion Criteria: * A sample of peripheral blood that is not accessible. * Insufficient clinical pathological information in the electronic clinical record. Elimination Criteria: * Withdrawal * Insufficient DNA quality and quantity for genomic sequencing analyses. * Lost of follow up
Where this trial is running
Mexico City, Mexico City
- Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología — Mexico City, Mexico City, Mexico (Recruiting)
Study contacts
- Principal investigator: Oscar G Arrieta Rodriguez, M.D., M.Sc. — Instituto Nacional de Cancerologia de Mexico
- Study coordinator: Oscar G Arrieta Rodriguez, M.D., M.Sc.
- Email: ogar@unam.mx
- Phone: 5556280400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.